A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
- Sex: Any
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase II
- Conditions Being Studied: Apolipoprotein L1
Study Purpose
The main purpose of this study is to evaluate the safety of MZE829 (an investigational drug) in adults with chronic kidney disease and a high-risk APOL1 gene; and to study the effects of MZE829 on the amount of protein in your urine.
Who Can Participate
Inclusion Criteria: 18-65 years old; APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2; chronic kidney disease with persistent albuminuria
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Minoff Health Center at Chagrin Highlands
3909 Orange Pl
Orange Village OH, 44122
- UH IRB: STUDY20250161
- StudyID: 2024-01613
- ClinicalTrials.gov: N/A
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422